Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first... Read more.
Morrow Sodali Acquires Australian Corporate Communication Consultancy, Domestique
Leading Global Stakeholder Engagement Advisory Firm Expands APAC Business, Advancing Strategy in Partnership with TPG SYDNEY–(BUSINESS WIRE)–Morrow Sodali... Read more.
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B
BE-101 is Company’s Lead Program in Hemophilia B; IND Filing Anticipated in Mid-2024 Be Bio Appoints Glenn Pierce, M.D., Ph.D., Hemophilia Physician-Researcher... Read more.
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Updated data from studies of beti-cel in 63 patients with transfusion-dependent beta-thalassemia showed sustained transfusion independence and improvements in iron... Read more.
NKLA DEADLINE TUESDAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Nikola Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKLA
NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nikola Corporation (NASDAQ: NKLA)... Read more.
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based... Read more.
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
ADI-001 showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL) Strong exposure... Read more.
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
NEW YORK–(BUSINESS WIRE)–Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are... Read more.
Teoayeah’s Christmas Gift List for All Kids (12/11-12/24)
HOUSTON–(BUSINESS WIRE)–The annual Christmas season is just around the corner and the festive spirit fills the air. In order to give every child a satisfying... Read more.
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients.... Read more.